Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Picard Medical, Inc.

PMI

Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.

Last trade $7.27
Day change +$0.03 (+0.41%)
Day range $7.07 – $7.86
Volume 17,181
Market cap $18M

Open XASE

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$17.8M
Price / earnings
—
Price / book
10.37×
Price / sales
2.83×
EV / sales
2.92×
EV / EBITDA
-1.19×

Profitability

Earnings per share
-$11.39
Return on assets
-305.37%
Return on equity
-1,631.29%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.38×
Current ratio
1.02×
Quick ratio
0.22×
Cash ratio
0.01×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16.07M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PMI, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025
Revenue$2.95M$1.15M$1.01M$1.19M
Cost of revenue$2.34M$875K$598K$1.32M
Gross profit$616K$275K$411K-$130K
Selling, general and administrative$3.87M$2.89M$2.87M$2.41M
Research and development$1.37M$1.9M$547K$951K
Total operating expenses$5.25M$4.79M$3.41M$3.36M
Operating income-$4.63M-$4.51M-$3M-$3.49M
Interest expense-$89K$0-$2.29M$0
Income before taxes-$5.65M-$7.62M-$4.29M-$10.43M
Income taxes$7K$0$4K$0
Net income-$5.66M-$7.62M-$4.29M-$10.43M
Net income attributable to common shareholders-$5.66M-$7.62M-$4.29M-$10.43M
EBITDA-$4.58M-$4.47M-$2.96M-$3.45M
Basic earnings per share-$3.05-$5.00-$2.91-$9.50
Diluted earnings per share-$3.05-$5.00-$2.91-$9.50

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Picard Medical Reports Third Quarter 2026 Financial Results; Gross Profit Positive for Third Consecutive Quarter; Net Loss Narrows 79% to $2.2 Million

Picard Medical reported Q3 2026 results showing positive gross profit for the third consecutive quarter, with net loss narrowing 79% to $2.2 million. Nine-month revenue increased 10% to $4.3 million with gross profit improving to $1.0 million from a prior-year loss. The company completed repayment of its Senior Secured Note and expects Q4 2026 product sales to exceed prior year, though it faces capital needs and substantial doubt about continuing as a going concern.

GlobeNewswire Inc.

Picard Medical Announces Reverse Stock Split Following Stockholder Approval to Support Continued NYSE American Listing Compliance

Picard Medical announced a 1-for-50 reverse stock split effective July 31, 2026, to maintain NYSE American listing compliance. The split was approved by stockholders on July 17, 2026. The company, parent of SynCardia Systems (maker of the FDA and Health Canada-approved total artificial heart), aims to position itself for growth while advancing its next-generation Emperor platform.

GlobeNewswire Inc.

Kuehn Law Encourages Investors of Picard Medical Inc. to Contact Law Firm

Kuehn Law is investigating whether officers and directors of Picard Medical Inc. breached fiduciary duties by failing to disclose a fraudulent stock promotion scheme involving social media misinformation, coordinated share dumping by insiders through offshore accounts, and omission of risk disclosures related to artificial trading activity that inflated stock prices.

GlobeNewswire Inc.

Picard Medical / SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies

Picard Medical announced successful completion of preclinical implant studies for its next-generation Emperor Total Artificial Heart (TAH) at University of Arizona and Banner University Medical Center. The Emperor TAH demonstrated stable hemodynamic support with an independent dual motor ventricular system designed to advance toward a fully implantable artificial heart system. Three acute implant procedures were completed with no device-related failures observed.

GlobeNewswire Inc.

Picard Medical / SynCardia to Present Next Generation Total Artificial Heart Platform at ISHLT 2026 in Toronto

Picard Medical, parent company of SynCardia Systems, announced its participation in the ISHLT 2026 Annual Meeting in Toronto. The company will present a poster on the Emperor Total Artificial Heart, a next-generation fully implantable solution for end-stage heart failure, and exhibit at booth 409 to showcase its SynCardia Total Artificial Heart technology.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Dec 29, 2008$0.125Jan 15, 2009unknown
Sep 26, 2008$0.125Oct 15, 2008unknown
Jun 26, 2008$0.625Jul 15, 2008unknown
Mar 27, 2008$0.625Apr 15, 2008unknown
Dec 27, 2007$2.625Jan 15, 2008unknown

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 3, 20261-for-50reverse split